WHAT IS KNOWN AND OBJECTIVE: Posterior reversible encephalopathy syndrome (PRES) can be the result of acute hypertension, eclampsia, renal failure and the use of immunosuppressive or cytotoxic agents. We report a case of PRES as a result of the use of pazopanib, a vascular endothelial growth factor inhibitor used for renal cell carcinoma (RCC). CASE SUMMARY: A 76-year-old man treated with RCC develops PRES shortly after the initiation of pazopanib. WHAT IS NEW AND CONCLUSION: There are no known reports of the association between PRES and pazopanib. We postulate that pazopanib can disrupt the normal endothelial function of the brain leading to the development of PRES.
WHAT IS KNOWN AND OBJECTIVE: Posterior reversible encephalopathy syndrome (PRES) can be the result of acute hypertension, eclampsia, renal failure and the use of immunosuppressive or cytotoxic agents. We report a case of PRES as a result of the use of pazopanib, a vascular endothelial growth factor inhibitor used for renal cell carcinoma (RCC). CASE SUMMARY: A 76-year-old man treated with RCC develops PRES shortly after the initiation of pazopanib. WHAT IS NEW AND CONCLUSION: There are no known reports of the association between PRES and pazopanib. We postulate that pazopanib can disrupt the normal endothelial function of the brain leading to the development of PRES.
Authors: Christina A K Kim; Julie Price-Hiller; Quincy S Chu; Keith Tankel; Ron Hennig; Michael B Sawyer; Jennifer L Spratlin Journal: Invest New Drugs Date: 2014-05-23 Impact factor: 3.850
Authors: Stephen J H Dobbin; Alan C Cameron; Mark C Petrie; Robert J Jones; Rhian M Touyz; Ninian N Lang Journal: Heart Date: 2018-09-18 Impact factor: 5.994
Authors: Young Kwang Chae; Lauren Chiec; Scott K Adney; Josh Waitzman; Ricardo Costa; Benedito Carneiro; Maria Matsangou; Mark Agulnik; Peter Kopp; Frank Giles Journal: Oncotarget Date: 2018-06-15